Study of Adbelimumab with Chemotherapy and Apatinib as Pre-Surgery Treatment for Resectable Esophageal Squamous Cell Carcinoma

What this Trial Is About

Esophageal squamous cell carcinoma ESCC is a common and deadly digestive tract cancer with limited improvements in survival despite advances in surgery, radiotherapy, and chemotherapy. This trial focuses on patients with locally advanced, resectable ESCC, aiming to explore effective neoadjuvant treatments to reduce postoperative recurrence and improve survival. The study evaluates the safety and effectiveness of combining adbelimumab, chemotherapy, and apatinib before surgery for this condition. Participants will receive four cycles of preoperative neoadjuvant therapy with adbelimumab, albumin paclitaxel, carboplatin, and apatinib over 21-day cycles. Surgery, including minimally invasive esophagectomy techniques, will be performed 4 to 6 weeks after the last dose. Postoperative radiotherapy may be given based on the patients clinical and pathological status. Adbelimumab treatment can continue for up to one year. Patients will be monitored throughout the study until disease progression, withdrawal, loss to follow-up, or death. During the study, researchers will collect blood and tumor samples before and after treatment to study immune changes. They will assess outcomes such as pathological complete response one month after surgery, major pathological response, objective response before surgery, and survival rates up to five years. Safety will be monitored by recording treatment-related adverse events and surgical outcomes. Overall, participants will be closely followed to evaluate the treatments impact and safety over the study period.

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma